scholarly journals The Potential Cytotoxic Activity Enhancement of α-Mangostin in Chitosan-Kappa Carrageenan-Loaded Nanoparticle against MCF-7 Cell Line

Polymers ◽  
2021 ◽  
Vol 13 (11) ◽  
pp. 1681
Author(s):  
Nasrul Wathoni ◽  
Lisna Meylina ◽  
Agus Rusdin ◽  
Ahmed Fouad Abdelwahab Mohammed ◽  
Dorandani Tirtamie ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Physicochemical Properties ◽  
Polymeric Nanoparticles ◽  
Breast Cancer Therapy ◽  
Polymeric Nanoparticle ◽  
Nanoparticle Formulation ◽  
Kappa Carrageenan ◽  
Mcf 7

α-mangostin (αM), a xanthone derivative compound isolated from the extract of mangosteen pericarp (Garcinia mangostana L), has potential anticancer properties for breast cancer. However, it has poor solubility in water and low selectivity towards cancer cells. The polymeric nanoparticle formulation approach can be used to overcome these problems. In this study, a chitosan biopolymer-based αM polymeric nanoparticle formulation was encapsulated using kappa carrageenan (αM-Ch/Cr) as a novel carrier for breast cancer therapy and evaluated for their physicochemical properties, drug release profile, and in vitro cytotoxicity against breast cancer cells (MCF-7). Polymeric nanoparticles formulated with varying concentrations of kappa carrageenan were successfully prepared by ionic gelation and spray pyrolysis techniques. αM-Ch/Cr nanoparticles formed perfectly round particles with a size of 200–400 nm and entrapment efficiency ≥ 98%. In vitro release studies confirmed that αM-Ch/Cr nanoparticles had a sustained release system profile. Interestingly, the formulation of polymeric nanoparticles significantly (p < 0.05) increased the cytotoxicity of αM against MCF-7 cell with IC50 value of 4.7 μg/mL compared to the non-nanoparticle with IC50 of 8.2 μg/mL. These results indicate that αM-Ch/Cr nanoparticles have the potential to improve the physicochemical properties and cytotoxicity effects of αM compounds as breast cancer therapy agents.

scholarly journals A GSH/CB Dual-Controlled Self-Assembled Nanomedicine for High-Efficacy Doxorubicin-Resistant Breast Cancer Therapy

2022 ◽  
Vol 12 ◽  
Author(s):  
Yang Yang ◽  
Quanfeng Zhao ◽  
Zhe Peng ◽  
Yunjiang Zhou ◽  
Miao-Miao Niu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Adverse Reactions ◽  
Caspase 3 ◽  
Anticancer Agent ◽  
High Efficacy ◽  
Breast Cancer Therapy ◽  
Mcf 7

Chemoresistance is a major therapeutic obstacle in the treatment of breast cancer. Therefore, how to overcome chemoresistance is a problem to be solved. Here, a glutathione (GSH)/cathepsin B (CB) dual-controlled nanomedicine formed by cyclic disulfide-bridged peptide (cyclic-1a) as a potent anticancer agent is reported. Under the sequential treatment of GSH and CB, cyclic-1a can efficiently self-assemble into nanofibers. In vitro studies show that cyclic-1a promotes the apoptosis of MCF-7/DOX cells by inducing the cleavages of caspase-3 and PARP. In vivo studies confirm that cyclic-1a significantly inhibits the progression of MCF-7/DOX cells-derived xenograft in nude mice, with no obvious adverse reactions. This study provides a paradigm of GSH/CB dual-controlled nanomedicine for high-efficacy and low-toxic DOX-resistant breast cancer therapy.

scholarly journals Hydrogel-Mediated DOX⋅HCl/PTX Delivery System for Breast Cancer Therapy

2019 ◽  
Vol 20 (19) ◽  
pp. 4671
Author(s):  
Hoon Hyun ◽  
Young Yoo ◽  
So Kim ◽  
Hyun Ko ◽  
Heung Chun ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Therapy ◽  
Anticancer Effect ◽  
Breast Cancer Therapy ◽  
Glycol Chitosan ◽  
Burst Period ◽  
Delivery Approach ◽  
Dual Drug

We used a hydrogel-mediated dual drug delivery approach, based on an injectable glycol chitosan (GC) hydrogel, doxorubicin hydrochloride (DOX⋅HCl), and a complex of beta-cyclodextrin (β-CD) and paclitaxel (PTX) (GDCP) for breast cancer therapy in vitro and in vivo. The hydrogel was swollen over 3 days and remained so thereafter. After an initial burst period of 7 hours, the two drugs were released in a sustained manner for 7 days. The in vitro cell viability test showed that GDCP had a better anticancer effect than well plate and DOX⋅HCl/PTX (DP). In addition, the in vivo tests, which evaluated the anticancer effect, systemic toxicity, and histology, proved the feasibility of GDCP as a clinical therapy for breast cancer.

scholarly journals An analytical study of Trastuzumab-dendrimer-fluorine drug delivery system in breast cancer therapy in vitro

2021 ◽  
Vol 133 ◽  
pp. 111053
Author(s):  
Dorota Bartusik-Aebisher ◽  
Grzegorz Chrzanowski ◽  
Zuzanna Bober ◽  
David Aebisher
Keyword(s):  
Breast Cancer ◽  
Drug Delivery ◽  
Cancer Therapy ◽  
Drug Delivery System ◽  
Delivery System ◽  
Analytical Study ◽  
Breast Cancer Therapy

Novel folate-targeted docetaxel-loaded nanoparticles for tumour targeting: in vitro and in vivo evaluation

RSC Advances ◽  
2016 ◽  
Vol 6 (69) ◽  
pp. 64306-64314 ◽  
Author(s):  
M. H. Han ◽  
Z. T. Li ◽  
D. D. Bi ◽  
Y. F. Guo ◽  
H. X. Kuang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Folic Acid ◽  
Cancer Therapy ◽  
Targeted Delivery ◽  
Tumour Targeting ◽  
Breast Cancer Therapy ◽  
In Vivo Evaluation ◽  
Targeted Delivery System

Cholesterol-PEG1000-FA (folic acid) was synthesized as a stabilizer to encapsulate DTX, for the construction of a promising targeted delivery system for breast cancer therapy.

Sign in / Sign up

Export Citation Format

Share Document